Ruiz-Bañobre, Juan
Rodriguez-Casanova, Aitor
Costa-Fraga, Nicolas
Bao-Caamano, Aida
Alvarez-Castro, Ana
Carreras-Presas, Martín
Brozos-Vazquez, Elena
Vidal-Insua, Yolanda
Vazquez-Rivera, Francisca
Candamio-Folgar, Sonia
Mosquera-Presedo, Manuel
Lago-Lestón, Ramón M.
Muinelo-Romay, Laura
Vázquez-Bueno, José Ángel
Sanz-Pamplona, Rebeca
Moreno, Víctor
Goel, Ajay
Castillo, Lourdes
Martin, Ana C.
Arroyo, Rocio
Esteller, Manel
Crujeiras, Ana B.
López-López, Rafael
Díaz-Lagares, Angel
Funding for this research was provided by:
Instituto de Salud Carlos III (CM19/00087, FI19/00240, PI17-0009, CP17/0008, PI18/00307)
TTD Research Grant (2020)
Xunta de Galicia (IN853B 2018/03, IN606A-2020/004, IN853B 2018/03, PRIS3)
Fundación Científica Asociación Española Contra el Cáncer (GCTRA18022MORE)
AGAUR, Spain (2017SGR723)
National Institutes of Health (CA181572, CA184792, CA202797, CA214254)
Amadix
Institució Catalana de Recerca i Estudis Avançats
Merck Serono (2015)
Article History
Received: 22 April 2022
Accepted: 17 June 2022
First Online: 9 July 2022
Declarations
:
: This study was approved by the Galician Ethical Committee (2017/538) and conducted in accordance with the guidelines for Good Clinical Practice and the Declaration of Helsinki. Patients signed the informed consent to participate.
: Not applicable.
: J.R.-B. has received honoraria for educational activities from Roche; honoraria for consultancies from Boehringer Ingelheim; institutional research funding from Roche; and travel, accommodations, expenses from Bristol-Myers Squibb, Merck Sharp & Dohme, Ipsen, PharmaMar, Merck, Pfizer, and Roche. E.B.-V. has received honoraria for consultancies from Leo, and Rovi; and travel, accommodations, expenses from Servier, Merck, Sanofi, Roche, Pierre Fabre, and Amgen. Y.V.-I. has received honoraria for consultancies from PharmaMar. F.V.-R. has received honoraria for consultancies from Roche, Eisai, and Servier; and travel, accommodations, expenses from Lilly, Merck, and Pierre Fabre. S.C.-F. has received honoraria for educational activities from Servier, and Pierre Fabre; and travel, accommodations, expenses from Lilly, and Merck. R.L.-L. has received honoraria for participation in Advisory Boards from Roche, AstraZeneca, Merck, Merck Sharp & Dohme, Bayer, Bristol-Myers Squibb, Novartis, Janssen, Lilly, Pfizer, and Leo; travel, accommodations, and expenses from PharmaMar, Roche, Bristol-Myers Squibb, and Pierre Fabre; research funding from Roche and Merck; and is co-founder and shareholder in Nasasbiotech, S.L., Mtrap Inc. A.R.-C., A.B.C., R.L.-L. and A.D.-L. are inventors in one patent application over these results licensed to Advanced Marker Discovery, S.L. (Amadix). L.C., A.C.M. and R.A. are employees of Advanced Marker Discovery, S.L. (Amadix). The rest of the authors declare no potential conflicts of interest.